The nHCM Disease Biology That Demands Dedicated Drugs

Non-obstructive hypertrophic cardiomyopathy (nHCM) affects approximately 30% of HCM patients — those lacking resting or provoked left ventricular outflow tract (LVOT) obstruction — and carries a disproportionately high burden of life-threatening ventricular arrhythmias compared to its obstructive counterpart, despite a similar risk of heart failure and all-cause mortality. This distinction, documented explicitly in Cytokinetics' multi-jurisdictional patent filings, is the core biological rationale for treating nHCM as an independent drug development target rather than an off-label extension of obstructive HCM therapy.

At the molecular level, retrieved patent data from MyoKardia, Inc. describes HCM as caused by "one or more of over 1,000 known point mutations" in sarcomere proteins, with cardiac sarcomere hypercontractility as the proximal driver. In both obstructive and non-obstructive subtypes, excessive myosin-actin crossbridge formation in systole and diastole produces hyperdynamic contraction and impaired relaxation (lusitropic dysfunction). Over time, this mechanical stress drives myocyte hypertrophy, myofilament disarray, microvascular remodelling, and fibrosis — a progressive remodelling cascade that ultimately increases arrhythmia substrate in nHCM patients.

Critically, academic literature retrieved from Sapienza University of Rome documents 139 differentially expressed microRNAs from a 1,128-miR panel in HCM patients, signalling that non-sarcomeric regulatory layers are co-contributors to the HCM phenotype. This multilayered biology — sarcomeric, genetic, and epigenetic — is now reflected in the diversity of therapeutic modalities entering the nHCM pipeline, as tracked by PatSnap's innovation intelligence platform.

Cardiac Myosin Inhibitors: From oHCM Validation to nHCM Labelling

Aficamten (CK-3773274, also called CK-274) from Cytokinetics, Incorporated is the first cardiac myosin inhibitor with explicit patent claims directed to nHCM as a primary indication — a commercially and clinically significant distinction that separates it from the broader HCM treatment landscape. Multiple Cytokinetics filings across Australia, India, New Zealand, Japan, and China describe methods for treating nHCM or HCM with mid-ventricular obstruction (MVO), using echocardiographic endpoints — specifically left ventricular ejection fraction (LVEF) — to titrate daily doses. Priority dates in these filings run from July 2022 through May 2023, consistent with Phase 2/3 trial initiation timelines.

"nHCM patients carry a higher burden of life-threatening ventricular arrhythmias — sustained ventricular tachycardia or ventricular fibrillation — compared to obstructive subtypes, motivating dedicated drug development for this underserved 30% of HCM patients."

Mavacamten (a pyrimidinedione, formerly MYK-461) from MyoKardia/Bristol-Myers Squibb represents the most extensively patented asset in this dataset. Retrieved filings span at least 10 jurisdictions (WO, CA, AU, SG, MX, NZ, JP, CN) with treatment claims covering both obstructive and non-obstructive HCM subtypes and diastolic dysfunction. MyoKardia's 2022 WO and CA filings explicitly address treatment "in the absence of beta-blocker therapy or with reduced beta-blocker therapy," signalling that myosin inhibitors may enable de-escalation of background cardiac medications — a clinically meaningful combination strategy. According to WIPO, the global patent filing landscape for cardiac sarcomere-targeting therapeutics has accelerated substantially since 2020.

Both major programs incorporate titration algorithms into their patent claims. Cytokinetics describes real-time LVEF-guided dose adjustment for aficamten in nHCM patients, while PROLAIO, Inc. (WO, AU) has filed a system-level patent incorporating right ventricular function and pulmonary arterial pressure as cardiac performance correlates for tracking response to myosin inhibitor therapy. Signals from these filings suggest that adaptive dosing systems — rather than fixed-dose protocols — are emerging as the clinical standard for myosin inhibitor use in HCM, with echocardiographic monitoring integration as a potential regulatory and IP differentiator.

Next-Generation Scaffolds and the Freedom-to-Operate Opportunity

Edgewise Therapeutics, Inc. has filed a substantial multi-jurisdictional portfolio around structurally distinct cardiac myosin inhibitor scaffolds — 1,4-dihydroquinazolinone, azadihydroquinazolinone, fused thiadiazine dioxide, and quinolinone amide compounds — that are chemically differentiated from the pyrimidinedione scaffolds of both mavacamten and aficamten. Patents span WO, AU, NZ, CA, IN, JP, and CN jurisdictions, with provisional priority dates from 2022–2023, placing development stage at preclinical to early clinical.

The mechanism is analogous to pyrimidinediones — suppression of excess myosin-actin crossbridge formation — but the distinct chemical scaffolds potentially offer differentiated pharmacokinetic/pharmacodynamic profiles or improved safety margins. For IP strategists, these filings create both risk and opportunity: Edgewise's dihydroquinazolinone and quinolinone amide platforms may occupy blocking positions in the broader cardiac myosin inhibitor class, or alternatively offer a route to complementary differentiation through HFpEF and diastolic dysfunction claims not yet occupied by the leading pyrimidinedione programs.

Shanghai Hengrui Pharmaceutical Co., Ltd. (Hengrui Medicine) has filed a CN patent (2024) on pyrimidinedione derivatives as myosin inhibitors for HCM, signalling domestic Chinese development of this target class. The Hengrui filing explicitly cites SRX disruption via MYH7 mutations as the therapeutic rationale — elevated myosin ATPase activity, reduced SRX ratio, and excess crossbridge formation — mirroring the mechanistic framing of the US and EU-origin programs. According to the European Patent Office, cardiac sarcomere-targeted therapeutics represent one of the most rapidly expanding patent classes in cardiovascular medicine.

Gene Therapy, RNAi, and microRNA Approaches Targeting the Root Cause

While small-molecule myosin inhibitors address downstream sarcomere hyperactivity, a parallel wave of genetic and RNA-targeting approaches aims to correct the upstream molecular defects driving HCM — including nHCM. Three distinct strategies emerge from retrieved patent records: AAV-based gene replacement, allele-specific RNA silencing (RNAi), and microRNA inhibition.

AAV-Based MYBPC3 Gene Therapy

Dynacor Company has filed a 2025 CN patent disclosing recombinant AAV (rAAV) gene therapy vectors designed to restore functional cardiac myosin binding protein C (cMyBP-C) expression in HCM patients with MYBPC3 mutations. MYBPC3 mutations causing reduced functional cMyBP-C levels represent a tractable gene therapy target because cMyBP-C is a critical regulator of sarcomere contractility — its loss or dysfunction directly amplifies the crossbridge formation excess that characterises HCM. The Dynacor 2025 filing signals renewed commercial interest in this approach, though the gap between this preclinical program and the advanced clinical myosin inhibitor programs remains substantial.

Allele-Specific RNA Silencing

President and Fellows of Harvard College have filed patents (WO, CA, AU — 2015) disclosing allele-specific RNA silencing for HCM, dilated cardiomyopathy (DCM), and left ventricular non-compaction (LVNC). The approach uses RNAi to selectively silence disease-causing dominant-negative sarcomere mutations while sparing the wild-type allele — a precision genetic strategy supported by NIH grants (U01 HL098166; R01 HL084553). Some of these filings are listed as inactive, suggesting they did not progress to active commercial prosecution, though the scientific rationale remains valid. Research published by institutions including NIH-funded groups continues to validate RNA silencing as a therapeutic modality for inherited cardiac disorders.

MicroRNA Targeting: miR-208 and miR-499

The Board of Regents of the University of Texas System has filed patents describing inhibition of miR-208 (which drives beta-myosin heavy chain expression) and miR-499 as a dual-targeting strategy for cardiac disorders. Retrieved patent data demonstrates that simultaneous downregulation of miR-208a and miR-499 produces synergistic effects on stress-related gene expression with faster onset than single-target suppression — an RNA combinatorial strategy potentially applicable to HCM disease modification. Separately, Medizinische Hochschule Hannover describes oligonucleotide inhibition of miR-132 for cardiac and fibrotic disorders. These miRNA-targeting patents are listed as inactive or early-stage, but the underlying biology is corroborated by the Sapienza University of Rome literature data identifying 139 differentially expressed miRs in HCM patient plasma from a 1,128-miR panel.

Biomarker Evidence: VEGF, hsCRP, and the Non-Sarcomeric Disease Layer

Academic literature retrieved from clinical cohorts provides quantitative evidence that nHCM pathophysiology extends well beyond sarcomere mechanics — with microvascular dysfunction, inflammation, and RNA regulatory networks contributing measurably to disease burden and outcomes.

A study from University Hospital in Hradec Kralove (Czech Republic) assessed serum VEGF specifically in 21 non-obstructive HCM patients, finding markedly elevated VEGF at 199 ng/L versus 20 ng/L in controls (P<0.001). This elevation correlated with left atrium diameter (r=0.51) and inversely with LVEF (r=-0.56), providing direct evidence for microvascular dysfunction and angiogenic signalling as co-contributors to nHCM pathophysiology — a target class not represented by any active commercial patent in this dataset.

A separate study from Fuwai Hospital and Peking Union Medical College — involving 490 HCM patients with a follow-up of 3.7 ± 2.0 years — established elevated high-sensitivity C-reactive protein (hsCRP) as a significant independent predictor of cardiovascular death (adjusted HR 5.41) and sudden cardiac death. This inflammatory signal, documented in a large HCM cohort, suggests that inflammatory pathways represent an ancillary target distinct from direct sarcomere intervention — one that is currently unaddressed by the commercial patent landscape in this dataset. Research published in journals indexed by Nature and other peer-reviewed outlets continues to build the mechanistic case for inflammatory co-targeting in HCM.

Apical HCM (ApHCM) — a non-obstructive HCM variant — is documented in a University College London study (42 ApHCM patients vs. 36 controls) to cause functional limitation on cardiopulmonary exercise testing in 35% of patients, associated with impaired myocardial mechanics and reduced stress apical myocardial blood flow. This provides clinical evidence that non-obstructive HCM variants produce objective functional impairment requiring pharmacological intervention, reinforcing the unmet need for dedicated nHCM therapeutics beyond symptom management.

Strategic Implications for IP and Drug Development Teams

The nHCM patent landscape is at a critical inflection point: what was previously an off-label extension of obstructive HCM therapy is now becoming an explicit, commercially prosecuted indication in its own right. Several strategic signals from this dataset warrant attention from IP counsel, pipeline strategists, and R&D leaders working in cardiovascular medicine.

nHCM is becoming an explicit labeled indication. Cytokinetics' multi-jurisdictional aficamten patent estate for nHCM — active filings in AU, IN, NZ, JP, and CN as of 2025, with priority dates from 2022–2023 — constitutes the most significant commercial IP signal in this dataset for non-obstructive HCM. This is a previously underserved population representing approximately 30% of all HCM patients, and the explicit labelling intent signals that nHCM will likely become a standalone regulatory indication rather than a subset of broader HCM approvals.

Chemical scaffold diversification creates freedom-to-operate opportunities. Edgewise Therapeutics' dihydroquinazolinone and quinolinone amide platforms occupy chemically differentiated space from the pyrimidinedione scaffolds of mavacamten and aficamten. IP strategists should monitor these filings across WO, AU, NZ, CA, IN, JP, and CN for potential blocking positions in the broader cardiac myosin inhibitor class, or complementary differentiation through HFpEF and diastolic dysfunction claims. The USPTO prosecution history of these applications will be an important signal to track.

Gene therapy and RNAi face a long development horizon but address the genetic root cause. MYBPC3-targeted rAAV gene therapy (Dynacor, 2025) and allele-specific RNAi (Harvard, 2015; some lapsed) target the approximately 40–50% of genotype-positive HCM patients with MYBPC3 mutations. The Dynacor 2025 filing signals renewed commercial interest, but the gap between these preclinical approaches and the advanced clinical myosin inhibitor programs remains substantial. Teams monitoring this space should track both the Dynacor CN application and any corresponding international filings.

The inflammatory and microRNA biology of HCM represents unexploited commercial white space. Retrieved literature from Fuwai Hospital (hsCRP as an independent predictor of cardiovascular death with adjusted HR 5.41 in 490 HCM patients) and Sapienza University of Rome (139 differentially expressed miRs in HCM plasma from a 1,128-miR panel) indicate measurable non-sarcomeric disease drivers in HCM that lack corresponding active commercial patent claims in this dataset. For mechanism-differentiated drug developers, this represents a potential first-mover opportunity in nHCM inflammatory or RNA regulatory targeting.

"139 differentially expressed microRNAs from a 1,128-miR panel were identified in HCM patient plasma — yet no active commercial patent in this dataset targets the miRNA regulatory network specifically in non-obstructive HCM, representing a measurable white space in the pipeline."

Echocardiographic response-guided dosing is emerging as a competitive differentiator. Both major cardiac myosin inhibitor programs incorporate titration algorithms into their patent claims — LVEF-guided dose adjustment for aficamten in nHCM (Cytokinetics), and right ventricular function and pulmonary arterial pressure monitoring in the PROLAIO system. Pharmacovigilance and monitoring integration may become a key IP and regulatory differentiation strategy, particularly given LVEF safety considerations inherent to this drug class. Drug development teams should consider whether integrated monitoring protocols belong in their own IP strategy as well as in clinical trial design.